• Cadrenal Therapeutics reported a positive FDA Type D meeting supporting its Phase 3 registration study plan for CAD-1005 in HIT.
• No clinical results were presented; the update outlined regulatory alignment ahead of the Phase 3 trial.
• FDA backed the primary endpoint approach focused on whether patients develop new or worsening clot-related events during treatment.
• The Phase 3 study will use placebo alongside standard anticoagulation in both arms, supporting a controlled readout for potential approval.
• Management cited a $2 billion peak annual revenue opportunity for CAD-1005, targeting about 50,000 acute HIT diagnoses annually in the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310800PRIMZONEFULLFEED9818075) on August 31, 2026, and is solely responsible for the information contained therein.